Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Li, Xiaojin ^a   Guo, Hua ^a   Duan, Hongyang ^b   Yang, Yanlian ^b   Meng, Jie ^a   Liu, Jian ^a   Wang, Chen ^b   Xu, Haiyan ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b NATIONAL CENTER FOR NANOSCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; CYCLOPHOSPHAMIDE; STROMAL CELL DERIVED FACTOR 1; VINCRISTINE;

ANIMAL; APOPTOSIS; BONE MARROW; CELL ADHESION; CELL MOTION; DRUG EFFECTS; FEMALE; HL-60 CELL LINE; HUMAN; LEUKEMIA, MYELOID, ACUTE; MESENCHYMAL STROMA CELL; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; U-937 CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; CYCLOPHOSPHAMIDE; FEMALE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; U937 CELLS; VINCRISTINE;

EID: 84946592745     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16228     Document Type: Article

References (56)

1. Löwenberg, B., Downing, J. R. & Burnett, A. Acute myeloid leukemia. N Engl J Med. 14, 1051-1062 (1999).
2. Tavor, S. & Petit, I. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia. Semin Cancer Biol. 20, 178-185 (2010).
3. Li, Z. W. & Dalton, W. S. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev. 20, 333-342 (2006).
4. Ishikawa, F. et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 25, 1315-1321 (2007).
5. Konopleva, M. & Andreeff, M. Targeting the leukemia microenvironment. Curr Drug Targets. 8, 685-701 (2007).
6. Meads, M. B., Hazlehurst, L. A. & Dalton, W. S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res. 14, 2519-2526 (2008).
7. Domanska, U. M. et al. A review on CXCR4/CXCL12 axis in oncology: no place to hide. Eur J Cancer. 49, 219-230 (2013).
8. Burger, J. A. & Bürkle, A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 137, 288-296 (2007).
9. Konopleva, M. et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16, 1713-1724 (2002).
10. Manabe, A., Coustan-Smith, E., Behm, F. G., Raimondi, S. C. & Campana, D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 79, 2370-2377 (1992).
11. Panayiotidis, P., Jones, D., Ganeshaguru, K., Foroni, L. & Hoffbrand, A. V. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 92, 97-103 (1996).
12. Basak, P. et al. Leukemic stromal hematopoietic microenvironment negatively regulates the normal hematopoiesis in mouse model of leukemia. Chin J Cancer. 29, 969-979 (2010).
13. Burger, J. A. et al. J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 96, 2655-2663 (2000).
14. Burger, J. A. & Kipps, T. J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107, 1761-1767 (2006).
15. Burger, J. A. & Peled, A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 23, 43-52 (2009).
16. Juarez, J., Bradstock, K. F., Gottlieb, D. J. & Bendall, L. J. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 17, 1294-300 (2003).
17. Nervi, B. et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113, 6206-6214 (2009).
18. Uy, G. L. et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 119, 3917-3924 (2012).
19. Zeng, Z. et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215-6224 (2009).
20. Zeng, Z. et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 5, 3113-3121 (2006).
21. Parameswaran, R., Yu, M., Lim, M., Groffen, J. & Heisterkamp, N. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 25, 1314-1323 (2011).
22. Burger, M. et al. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106, 1824-1830 (2005).
23. Juarez, J. et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 21, 1249-1257 (2007).
24. Li, X. et al. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo. Sci Rep. 4, 6610 (2014).
25. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2015. CA Cancer J Clin. 65, 5-29 (2015).
26. Spoo, A. C., Lübbert, M., Wierda, W. G. & Burger, J. A. CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood 109, 786-791 (2007).
27. Peled, A. & Tavor, S. Role of CXCR4 in the pathogenesis of acute myeloid leukemia. Theranostics 3, 34-39 (2013).
28. Ahn, J. Y., Seo, K., Weinberg, O. K. & Arber, D. A. The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol. 21, 79-84 (2013).
29. Imai, K. et al. Selective secretion of chemoattractants for haemopoietic progenitor cells by bone marrow endothelial cells: a possible role in homing of haemopoietic progenitor cells to bone marrow. Br J Haematol. 106, 905-911 (1999).
30. Juarez, J., Bendall, L. & Bradstock, K. Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. Curr Pharm Des. 10, 1245-1259 (2004).
31. Harris, N. L. et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 10, 1419-1432 (1999).
32. Weisberg, E. et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 26, 985-990 (2012).
33. Tavor, S. et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res. 64, 2817-2824 (2004).
34. Kawaguchi, A. et al. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood 114, 2961-2968 (2009).
35. Trent, J. O. et al. Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem. 278, 47136-47144 (2003).
36. Zhang, W. B. et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem. 277, 24515-24521 (2002).
37. Moyle, G. et al. Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1. Clin Infect Dis. 48, 798-805 (2009).
38. Stone, N. D. et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother. 51, 2351-2358 (2007).
39. Peng, S. B. et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 14, 480-490 (2015).
40. Ahles, T. A. et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 20, 485-493 (2002).
41. Partridge, A. H., Burstein, H. J. & Winer, E. P. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 30, 135-142 (2001).
42. Schwartz, C. L. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist 4, 45-54 (1999).
43. Debnath, B., Xu, S., Grande, F., Garofalo, A. & Neamati, N. Small molecule inhibitors of CXCR4. Theranostics 3, 47-75 (2013).
44. Lefrançois, M. et al. Agonists for the Chemokine Receptor CXCR4. ACS Med Chem Lett. 2, 597-602 (2011).
45. Tamamura, H. et al. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives. Org Biomol Chem. 1, 3656-3662 (2003).
46. Schinkel, A. H. & Jonker, J. W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 55, 3-29 (2003).
47. Leslie, E. M., Deeley, R. G. & Cole, S. P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 204, 216-237 (2005).
48. Zhang, F. Y. et al. Naringenin enhances the anti-tumor effect of doxorubicin through selectively inhibiting the activity of multidrug resistance-associated proteins but not P-glycoprotein. Pharm Res. 26, 914-925 (2009).
49. Wang, J. et al. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells. J Pharm Sci. 100, 2267-2277 (2011).
50. Mi, Y. J. et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 70, 7981-7991 (2010).
51. Müller, A. et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56 (2001).
52. Burger, M. et al. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene 22, 8093-8101 (2003).
53. Kijima, T. et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 62, 6304-6311 (2002).
54. Scala, S. et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 11, 1835-1841 (2005).
55. Wang, J. et al. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal. 17, 1578-1592 (2005).
56. Scotton, C. J. et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 62, 5930-5938 (2002).